OABIW
OmniAb Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.87
52W High
$0.36
52W Low
$0.08
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About OmniAb Inc.
OmniAb Inc. is a leading biotechnology company focused on the development of fully human therapeutic antibodies through its proprietary OmniAb platform. This innovative platform facilitates the creation of highly diverse antibody libraries, positioning OmniAb at the forefront of drug development, particularly in oncology and autoimmune diseases. With a robust pipeline and strategic partnerships, the company is well-equipped to capitalize on the escalating demand for advanced antibody therapies, aligning with industry trends in biotechnology and personalized medicine to enhance patient outcomes and drive future growth.
Fundamentals
| Revenue (TTM) | $18.67M |
| Gross Profit (TTM) | $18.36M |
| EBITDA | $-46.89M |
| Operating Margin | -147.40% |
| Return on Equity | -23.40% |
| Return on Assets | -13.00% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $1.85 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.50% |
| Shares Outstanding | 0 |
| Float | $97.38M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/9/2026